STING1 and cancer: IRF3 then moves to the nucleus and aids in the expression of IFN type I. Upregulation of the immune system via IFN type I is a well-known phenomenon, therefore STING agonist agents could be a potential novel therapy in cancer via the immune regulatory role of this pathway [118].